NSF

Across TCGA pan-cancer cohorts, NSF mass-spec protein is linked to patient survival in 7 of 34 cancer types, making it a survival-associated NSF data layer compared with 22 for mass-spec protein and 6 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher NSF mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated NSF expression acts as an unfavorable survival marker, although some lineages such as PDAC and COAD show a favorable association.

PDAC, COAD, and UCEC are the cancer types where NSF mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Tertile	All	0.479	0.293	.003	33	view →
COAD	DFS	Median	II,III,IV	1.000	0.887	.028	30	view →
UCEC	OS	Median	All	1.000	0.841	.002	20	view →
CCRCC	DFS	Median	II,III,IV	0.855	0.587	.011	9	view →
LUAD	OS	Median	III,IV	0.911	0.345	.026	7	view →
GBM	DFS	Quartile	All	0.275	0.519	.035	2	view →
HNSC	DFS	Median	III,IV	0.939	1.000	.043	1	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

NSF–PDAC (DFS)

Open the PDAC breakdown →